

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Katherine Galvin, *et al*

Serial No.: 09/635,521

Filed: August 9, 2000

For: *METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF
CARDIOVASCULAR AND TUMORIGENIC
DISEASE USING 4941*

Attorney Docket No.: MNI-094

Group Art Unit: 1636

Examiner: Loeb, Bronwen

14B

Zeta

11-17-02


Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the Honorable Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

November 14, 2002

Date



Maria C. Laccotripe Zacharakis, Ph.D. Limited Recognition Under 37 CFR §10.9(b)

AMENDMENT AND RESPONSE TO OFFICE COMMUNICATION

Dear Sir:

This communication is submitted in response to the Office Communication dated November 6, 2002 (Paper No. 13) which issued in the above-referenced application. In response to the Office Action dated February 28, 2002 (Paper No. 9), please amend the application as follows:

In the Claims:

Please cancel claims 1-24 and 31-69, without prejudice, and amend claim 26 as follows:

B' 26. (Amended) The method of claim 25, wherein the disorder is a disorder associated with aberrant angiogenesis.